IDEXX Laboratories (IDXX) Stock Price, News & Analysis

Company Overview

IDEXX Laboratories, Inc. is a global leader in the development, manufacturing and distribution of diagnostic and information technology solutions for animal health, water testing and dairy markets. The company’s core business activities center on providing veterinarians and farmers with rapid, accurate diagnostic tools and services to improve animal care and productivity. IDEXX’s offerings span in-clinic diagnostic systems, reference laboratory testing, and software solutions that streamline practice management and enhance decision-making.

The company’s product portfolio includes immunoassay analyzers, hematology instruments, chemistry systems and consumables designed for use in companion animal and livestock settings. Point‐of‐care tests for infectious diseases, endocrine disorders and more enable veterinarians to receive results during patient visits. IDEXX Reference Laboratories complement in-clinic diagnostics with advanced testing services covering genetics, pathology and microbiology. In addition, IDEXX offers digital imaging, telehealth and practice management software to optimize workflow and support clinical excellence.

Founded in 1983 and headquartered in Westbrook, Maine, IDEXX has grown into a multinational enterprise serving customers in more than 175 countries. The company maintains a network of regional offices, manufacturing facilities and reference labs across North America, Europe, Asia-Pacific, Latin America and emerging markets. IDEXX’s global footprint is supported by ongoing investment in research and development, aimed at expanding diagnostic capabilities and enhancing connectivity across veterinary practices.

Under the leadership of Chairman, President and Chief Executive Officer Jonathan W. Ayers, IDEXX continues to pursue innovation in animal health diagnostics and data-driven practice management. The company’s emphasis on science-driven solutions and customer support has established it as a trusted partner for veterinarians, livestock producers and water quality experts worldwide.

Key Stats

• Today's Range: $626.24 to $642.01
• 50-Day Range: $514.61 to $682.78
• 52-Week Range: $356.14 to $688.12
• Volume: 373,548 shs
• Average Volume: 524,664 shs
• Market Capitalization: $50.72 billion
• P/E Ratio: 52.79
• Dividend Yield: N/A
• Price Target: $649.44
• Consensus Rating: Moderate Buy

IDEXX Laboratories Stock Analysis - MarketRank™

IDEXX Laboratories scored higher than 93% of companies evaluated by MarketBeat, and ranked 76th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

IDEXX Laboratories has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 13.83%

Earnings Growth

Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEXX Laboratories is 52.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 269.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEXX Laboratories is 52.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.37.

Price to Earnings Growth Ratio

IDEXX Laboratories has a PEG Ratio of 4.19. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IDEXX Laboratories has a P/B Ratio of 34.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.31% of the float of IDEXX Laboratories has been sold short.

Short Interest Ratio / Days to Cover

IDEXX Laboratories has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IDEXX Laboratories has recently decreased by 26.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEXX Laboratories does not currently pay a dividend.

Dividend Growth

IDEXX Laboratories does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -2.09

Percentage of Shares Shorted

2.31% of the float of IDEXX Laboratories has been sold short.

Short Interest Ratio / Days to Cover

IDEXX Laboratories has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IDEXX Laboratories has recently decreased by 26.21%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.28

News Sentiment

IDEXX Laboratories has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for IDEXX Laboratories this week, compared to 26 articles on an average week.

Search Interest

15 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,293,468.00 in company stock.

Percentage Held by Insiders

Only 0.98% of the stock of IDEXX Laboratories is held by insiders.

Percentage Held by Institutions

87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IDXX Stock Analysis - Frequently Asked Questions

How have IDXX shares performed this year?

IDEXX Laboratories' stock was trading at $413.44 on January 1st, 2025. Since then, IDXX shares have increased by 53.3% and is now trading at $633.95.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its earnings results on Monday, August, 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories's quarterly revenue was up 10.6% on a year-over-year basis.
Read the conference call transcript.

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' top institutional investors include Vanguard Group Inc. (12.34%), State Street Corp (4.44%), Geode Capital Management LLC (3.06%) and Bamco Inc. NY (2.54%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, Nimrata Hunt, Michael G Erickson, James F Polewaczyk, George Fennell, Kathy V Turner, Michael Lane, Sharon E Underberg, Daniel M Junius, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:IDXX
• CIK: 874716
• Web: www.idexx.com
• Phone: (207) 556-0300
• Fax: 207-556-4346
• Employees: 11,000
• Year Founded: 1983

Price Target and Rating

• Average Price Target for IDEXX Laboratories: $649.44
• High Price Target: $785.00
• Low Price Target: $520.00
• Potential Upside/Downside: +2.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $12.01
• Trailing P/E Ratio: 52.79
• Forward P/E Ratio: 53.14
• P/E Growth: 4.19
• Net Income: $887.87 million
• Net Margins: 24.41%
• Pretax Margin: 30.41%
• Return on Equity: 64.42%
• Return on Assets: 29.89%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 1.11
• Quick Ratio: 0.79

Sales & Book Value

• Annual Sales: $3.90 billion
• Price / Sales: 13.01
• Cash Flow: $12.18 per share
• Price / Cash Flow: 52.06
• Book Value: $18.23 per share
• Price / Book: 34.78

Miscellaneous

• Outstanding Shares: 80,000,000
• Free Float: 79,221,000
• Market Cap: $50.72 billion
• Optionable: Optionable
• Beta: 1.56